Good DD IMOCOn the plus side of their potential success is that there have been two previously FDA approved PDC drugs; specifically: Aminolevulinic Acid (ALA) and Photofrin®, which have been FDA approved for actinic keratosis (Rough, scaly patches of skin that are considered precancerous) and esophageal cancer, respectively. Theralase to their credit has tested their new TLD-1400 series of PDCs against these two FDA approved drugs and have demonstrated in documented scientific research that they are 668,000x more effective than ALA and 198x more effective than Photofrin®, while delivering a treatment with virtually no side effects. This bodes well for a successful Phase 1/2a clinical trial. The second plus in their corner is that their TLD-1400 series of drugs are nuclear acting, meaning that they enter cancer cells and lock onto the DNA of the cell, unlike ALA and Photofrin®. When light activated, this new class of PDCs destroy the cancer cell by what is called apoptosis or natural cell death, basically the cell dies of natural causes. The beauty of nuclear acting drugs is that it doesn’t matter if the cancer cell came from a mouse, an ostrich, a dolphin or a human, they are all destroyed with the same efficacy and safety profile, as these are all mammallian cells, known collectively as eukaryotes.opied from IHUB Message Board